Curable response to crizotinib in a patient with liver metastatic inflammatory myofibroblastic tumour carrying a TFG‐ROS1 fusion.
- Resource Type
- Case Study
- Authors
- Yan, Hualin; Du, Lanxin; Zheng, Tianying; Liu, Juxian
- Source
- Liver International. Dec2022, Vol. 42 Issue 12, p2900-2902. 3p. 1 Color Photograph, 1 Diagram.
- Subject
- *LIVER
*DESMOID tumors
*CRIZOTINIB
*ANAPLASTIC large-cell lymphoma
*METASTASIS
- Language
- ISSN
- 1478-3223
Abbreviations CT computed tomography IMT inflammatory myofibroblastic tumour TKI tyrosine kinase inhibitor Lay Summary Metastatic inflammatory myofibroblastic tumours (IMTs) are aggressive and refractory. Liver biopsy revealed an inflammatory myofibroblastic tumour (IMT) (Figure 1F), and next-generation sequencing of the tumour tissue identified a I TFG-ROS1 i fusion. Curable response to crizotinib in a patient with liver metastatic inflammatory myofibroblastic tumour carrying a TFG-ROS1 fusion. [Extracted from the article]